Antibody mimetics are organic compounds that, like antibodies, can specifically bind antigens, but that are not structurally related to antibodies. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa. (Antibodies are ~150 kDa.)
Common advantages over antibodies are better solubility, tissue penetration, stability towards heat and enzymes, and comparatively low production costs. Antibody mimetics are being developed as therapeutic and diagnostic agents.
^Ebersbach H, Fiedler E, Scheuermann T, et al. (September 2007). "Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein". J. Mol. Biol.372 (1): 172–85. doi:10.1016/j.jmb.2007.06.045. PMID17628592.
^Skerra A (June 2008). "Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities". FEBS J.275 (11): 2677–83. doi:10.1111/j.1742-4658.2008.06439.x. PMID18435758.
^Silverman J, Liu Q, Lu Q, et al. (December 2005). "Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains". Nat. Biotechnol.23 (12): 1556–61. doi:10.1038/nbt1166. PMID16299519.